Profound Medical Corp
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping… Read more
Profound Medical Corp (PROF) - Total Liabilities
Latest total liabilities as of September 2025: $10.16 Million USD
Based on the latest financial reports, Profound Medical Corp (PROF) has total liabilities worth $10.16 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Profound Medical Corp - Total Liabilities Trend (2014–2024)
This chart illustrates how Profound Medical Corp's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Profound Medical Corp Competitors by Total Liabilities
The table below lists competitors of Profound Medical Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
IFE Elevators Co Ltd
SHE:002774
|
China | CN¥873.41 Million |
|
Zhejiang Bofay Elec Co Ltd
SHE:001255
|
China | CN¥665.11 Million |
|
Changzhou Evergreen Technology Co. Ltd. A
SHE:001324
|
China | CN¥207.01 Million |
|
Kowloon Development Company Limited
F:KOX
|
Germany | €24.02 Billion |
|
Quest Holdings S.A
AT:QUEST
|
Greece | €542.66 Million |
|
Okea ASA
OL:OKEA
|
Norway | Nkr1.76 Billion |
|
C.E. Info Systems Limited
NSE:MAPMYINDIA
|
India | ₹1.41 Billion |
|
Supriya Lifescience Limited
NSE:SUPRIYA
|
India | ₹1.21 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down Profound Medical Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.32 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Profound Medical Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Profound Medical Corp (2014–2024)
The table below shows the annual total liabilities of Profound Medical Corp from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $9.81 Million | -22.93% |
| 2023-12-31 | $12.73 Million | +2.54% |
| 2022-12-31 | $12.42 Million | +101.95% |
| 2021-12-31 | $6.15 Million | -15.20% |
| 2020-12-31 | $7.25 Million | -53.52% |
| 2019-12-31 | $15.60 Million | +6.65% |
| 2018-12-31 | $14.63 Million | +33.89% |
| 2017-12-31 | $10.93 Million | +65.80% |
| 2016-12-31 | $6.59 Million | +26.55% |
| 2015-12-31 | $5.21 Million | +4968.41% |
| 2014-12-31 | $102.73K | -- |